This is a competitive renewal application for training grant support in pediatric oncology. The goal of this T32 program is to train physicians who will be the future academic leaders in basic and/or clinical pediatric oncology research and who will work to reduce the burden of cancer in the pediatric population. To accomplish this goal we have engaged a diverse and outstanding training faculty that embraces multiple areas of basic (wet bench), translational and clinical research. This experienced and highly accomplished group includes members of the Department of Pediatric Oncology at the Dana-Farber Cancer Institute (DFCI), the Division of Pediatric Hematology/Oncology at Boston Children's Hospital (BCH), and additional components of the Harvard Medical School (HMS). Particular emphasis is placed on close mentorship of trainees in the selection of mentors and in on-going oversight during their research. The T32 program provides training in oncology research at the postdoctoral level for 8 trainees, selected from the combined DFCI-BCH pediatric hematology/oncology fellowship program, who are in their second, third and fourth years of training. The program is committed to identifying and supporting the most promising fellows, including minority candidates. Over the past 45 years the DFCI-BCH fellowship program has trained over 200 individuals, many of whom are leaders of academic pediatric hematology/oncology programs. Continued T32 support will ensure the training of investigational pediatric oncologists, whose research will contribute immeasurably to the understanding and management of childhood cancers.
While great strides have been made in the diagnosis and treatment of pediatric cancers, much remains to be done. Cure of patient is often achieved with unacceptable side-effects, and for many solid tumors current therapy is inadequate. The best hope for reducing the burden of pediatric cancer is the training of committed researchers by an experienced and accomplished faculty that is involved in diverse aspects of basic and clinical research directly relevant to tackling these challenging problems in children.
|Chen, Liying; Alexe, Gabriela; Dharia, Neekesh V et al. (2018) CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. J Clin Invest 128:446-462|
|Greenzang, Katie A; Cronin, Angel M; Kang, Tammy et al. (2018) Parent understanding of the risk of future limitations secondary to pediatric cancer treatment. Pediatr Blood Cancer 65:e27020|
|Marron, Jonathan M; Jones, Emma; Wolfe, Joanne (2018) Is There Ever a Role for the Unilateral Do Not Attempt Resuscitation Order in Pediatric Care? J Pain Symptom Manage 55:164-171|
|Greenzang, Katie A; Dauti, Angela; Mack, Jennifer W (2018) Parent perspectives on information about late effects of childhood cancer treatment and their role in initial treatment decision making. Pediatr Blood Cancer 65:e26978|
|Ozuah, Nmazuo W; Marcus, Karen J; LaCasce, Ann S et al. (2018) Excellent Outcomes Following Response-based Omission of Radiotherapy in Children and Adolescents With Intermediate or High-risk Hodgkin Lymphoma. J Pediatr Hematol Oncol 40:e338-e342|
|Marron, Jonathan M; Cronin, Angel M; Kang, Tammy I et al. (2018) Intended and unintended consequences: Ethics, communication, and prognostic disclosure in pediatric oncology. Cancer 124:1232-1241|
|Guenther, Lillian M; Dharia, Neekesh V; Ross, Linda et al. (2018) A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma. Clin Cancer Res :|
|Stolte, Björn; Iniguez, Amanda Balboni; Dharia, Neekesh V et al. (2018) Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma. J Exp Med 215:2137-2155|
|Ng, Samuel Y; Yoshida, Noriaki; Christie, Amanda L et al. (2018) Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun 9:2024|
|Guerra, Rachel M; Bird, Gregory H; Harvey, Edward P et al. (2018) Precision Targeting of BFL-1/A1 and an ATM Co-dependency in Human Cancer. Cell Rep 24:3393-3403.e5|
Showing the most recent 10 out of 22 publications